Author: Gulli Arnason

The European Medicines Agency (EMA) authorises initiation of a Phase IIa study evaluating AT-001 in patients diagnosed with Alzheimer’s disease EMA grants Orphan Drug Designation (ODD) to AT-001 for hereditary cystatin C amyloid angiopathy (HCCAA), a rare familial dementia   REYKJAVIK, ICELAND – November 3, 2025 – Arctic Therapeutics (ATx), an Iceland-based clinical-stage biopharmaceutical company,…

Icelandic drug discovery and development company Arctic Therapeutics (ATx) today announced the publication of research in JAMA Neurology, which informs a possible therapeutic strategy to treat a rare form of familial dementia. N-acetylcysteine (NAC) shows promise to treat hereditary cystatin C amyloid angiopathy (HCCAA) HCCAA – a subtype of cerebral amyloid angiopathy (CAA) – is…